ASCENT-04/KEYNOTE-D19: Phase 3 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in 1L programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.